171 related articles for article (PubMed ID: 23150853)
21. Hepatobiliary agents and their role in LI-RADS.
Hope TA; Fowler KJ; Sirlin CB; Costa EA; Yee J; Yeh BM; Heiken JP
Abdom Imaging; 2015 Mar; 40(3):613-25. PubMed ID: 25287679
[TBL] [Abstract][Full Text] [Related]
22. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
23. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
24. Modern diagnosis and management of hepatocellular carcinoma.
Marrero JA; Welling T
Clin Liver Dis; 2009 May; 13(2):233-47. PubMed ID: 19442916
[TBL] [Abstract][Full Text] [Related]
25. Imaging techniques for the diagnosis of hepatocellular carcinoma and the evaluation of response to treatment.
Hussain HK; Barr DC; Wald C
Semin Liver Dis; 2014 Nov; 34(4):398-414. PubMed ID: 25369302
[TBL] [Abstract][Full Text] [Related]
26. Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication.
Corwin MT; Lee AY; Fananapazir G; Loehfelm TW; Sarkar S; Sirlin CB
AJR Am J Roentgenol; 2018 Jan; 210(1):85-90. PubMed ID: 29023148
[TBL] [Abstract][Full Text] [Related]
27. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience.
Lauenstein TC; Salman K; Morreira R; Heffron T; Spivey JR; Martinez E; Sharma P; Martin DR
AJR Am J Roentgenol; 2007 Sep; 189(3):663-70. PubMed ID: 17715115
[TBL] [Abstract][Full Text] [Related]
28. Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma.
Fowler KJ; Karimova EJ; Arauz AR; Saad NE; Brunt EM; Chapman WC; Heiken JP
Transplantation; 2013 Jun; 95(12):1506-11. PubMed ID: 23778569
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of liver imaging reporting and data system MRI on primary hepatocellular carcinoma].
Zhao W; Li W; Yi X; Pei Y; Liu H; Zhang L; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Apr; 41(4):380-7. PubMed ID: 27241148
[TBL] [Abstract][Full Text] [Related]
30. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
31. Advances of imaging for hepatocellular carcinoma.
Choi BI
Oncology; 2010 Jul; 78 Suppl 1():46-52. PubMed ID: 20616584
[TBL] [Abstract][Full Text] [Related]
32. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.
Sapisochin G; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2011 Aug; 17(8):934-42. PubMed ID: 21438129
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
34. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
[TBL] [Abstract][Full Text] [Related]
35. CT and MRI of hepatocellular carcinoma: an update.
Ayyappan AP; Jhaveri KS
Expert Rev Anticancer Ther; 2010 Apr; 10(4):507-19. PubMed ID: 20397916
[TBL] [Abstract][Full Text] [Related]
36. Design and implementation of handheld and desktop software for the structured reporting of hepatic masses using the LI-RADS schema.
Clark TJ; McNeeley MF; Maki JH
Acad Radiol; 2014 Apr; 21(4):491-506. PubMed ID: 24594419
[TBL] [Abstract][Full Text] [Related]
37. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular cancer: optimal strategies for screening and surveillance.
Cabibbo G; Craxì A
Dig Dis; 2009; 27(2):142-7. PubMed ID: 19546552
[TBL] [Abstract][Full Text] [Related]
39. CT and MR imaging of hepatocellular carcinoma.
Bolog N; Andreisek G; Oancea I; Mangrau A
J Gastrointestin Liver Dis; 2011 Jun; 20(2):181-9. PubMed ID: 21725516
[TBL] [Abstract][Full Text] [Related]
40. Clinical mimicry of hepatocellular carcinoma: imaging-pathological correlation.
Chung YF; Thng CH; Lui HF; Mancer K; Chow PK; Tan YM; Cheow PC; Ooi LL
Singapore Med J; 2005 Jan; 46(1):31-6; quiz 37. PubMed ID: 15633007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
